H.C. Wainwright stated on Thursday that Sarepta Therapeutics’ (SRPT) recent divestiture in Arrowhead (ARWR) weakened its ...

SRPT rallies after Q2 earnings and revenue beat expectations as Elevidys deliveries resume following FDA clearance.

Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.

Sarepta Therapeutics ( ($SRPT) ) has shared an update. Sarepta Therapeutics announced a strategic restructuring and pipeline prioritization, ...

Fintel reports that on May 14, 2024, Oppenheimer upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from Perform to Outperform. As of May 8, 2024, the average one-year price target ...

Analysts expect Sarepta Therapeutics to report an earnings per share (EPS) of $1.01. The announcement from Sarepta ...

Shares of Sarepta Therapeutics ( NASDAQ: SRPT) rose on Wednesday after the market as it reported second quarter revenue and ...

SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT Provided by PR Newswire Jul 21, 2025, 8:15:00 AM ...

Sarepta Therapeutics said on Monday it will resume shipping of its muscular disorder gene therapy to patients who can walk, sending the company's shares 59% higher in extended trading.

Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options begin trading this week, for the February 2023 expiration. One of the key data points that goes into the price an option buyer ...